James Dentzer, Curis CEO
Corrected: FDA allows Curis to restart enrolling patients in leukemia trial as shares tumble 9%
Less than two weeks after the FDA lifted a hold on one of Curis’ programs, regulators are back with some good news.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
